These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 30321070)

  • 1. Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults.
    Grassi G; Pallanti S
    Expert Opin Pharmacother; 2018 Oct; 19(14):1541-1550. PubMed ID: 30321070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obsessive compulsive disorder and the glutamatergic system.
    Kariuki-Nyuthe C; Gomez-Mancilla B; Stein DJ
    Curr Opin Psychiatry; 2014 Jan; 27(1):32-7. PubMed ID: 24270485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.
    Marinova Z; Chuang DM; Fineberg N
    Curr Neuropharmacol; 2017; 15(7):977-995. PubMed ID: 28322166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Glutamate and the Immune Systems: New Targets for the Pharmacological Treatment of OCD.
    Marazziti D; Albert U; Mucci F; Piccinni A
    Curr Med Chem; 2018; 25(41):5731-5738. PubMed ID: 29119912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications.
    Vlček P; Polák J; Brunovský M; Horáček J
    Pharmacopsychiatry; 2018 Nov; 51(6):229-242. PubMed ID: 28950396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
    JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Novel treatment strategies for refractory patients with obsessive-compulsive disorder].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2013; 115(9):997-1003. PubMed ID: 24228478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder.
    Wald R; Dodman N; Shuster L
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):191-7. PubMed ID: 19586234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for a Systematic Review and Meta-Analysis of Lithium, Anticonvulsive or atypical antipsychotic Drugs for Treatment of Refractory Obsessive-Compulsive Disorder.
    Soleimani R; Jalali MM; Keshtkar A; Jalali SM
    J Med Life; 2017; 10(4):208-215. PubMed ID: 29362595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.
    Kushner MG; Kim SW; Donahue C; Thuras P; Adson D; Kotlyar M; McCabe J; Peterson J; Foa EB
    Biol Psychiatry; 2007 Oct; 62(8):835-8. PubMed ID: 17588545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.
    Pittenger C; Brennan BP; Koran L; Mathews CA; Nestadt G; Pato M; Phillips KA; Rodriguez CI; Simpson HB; Skapinakis P; Stein DJ; Storch EA
    Psychiatry Res; 2021 Jun; 300():113853. PubMed ID: 33975093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic treatment of obsessive-compulsive disorder comorbidity.
    Pallanti S; Grassi G
    Expert Opin Pharmacother; 2014 Dec; 15(17):2543-52. PubMed ID: 25252717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive-coping therapy for obsessive-compulsive disorder: a randomized controlled trial.
    Ma JD; Wang CH; Li HF; Zhang XL; Zhang YL; Hou YH; Liu XH; Hu XZ
    J Psychiatr Res; 2013 Nov; 47(11):1785-90. PubMed ID: 23988179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.
    Andersson E; Hedman E; Enander J; Radu Djurfeldt D; Ljótsson B; Cervenka S; Isung J; Svanborg C; Mataix-Cols D; Kaldo V; Andersson G; Lindefors N; Rück C
    JAMA Psychiatry; 2015 Jul; 72(7):659-67. PubMed ID: 25970252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis.
    Xia J; Du Y; Han J; Liu G; Wang X
    Drug Des Devel Ther; 2015; 9():2101-17. PubMed ID: 25960632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder.
    Wilhelm S; Buhlmann U; Tolin DF; Meunier SA; Pearlson GD; Reese HE; Cannistraro P; Jenike MA; Rauch SL
    Am J Psychiatry; 2008 Mar; 165(3):335-41; quiz 409. PubMed ID: 18245177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs to treat obsessive-compulsive disorder.
    Pallanti S; Grassi G; Cantisani A
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):67-77. PubMed ID: 24377420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.